Albumin is the major carrier protein for PFOS, PFOA, PFHxS, PFNA and PFDA in human plasma

Forsthuber, Martin; Kaiser, Andreas M.; Granitzer, Sebastian; Hassl, Ingrid; Hengstschläger, Markus; Stangl, Herbert; Gundacker, Claudia

doi:10.1016/j.envint.2019.105324

Cited by 138 publications

(99 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Once an individual is exposed to these chemicals, these chemicals bind to blood proteins and accumulate in the blood and blood-rich tissues, such as the kidney and liver [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] . For biological interrogation of PFAS exposure, analyses are typically carried out in blood matrices (e.g., plasma), blood rich tissues (e.g., liver); however, PFAS have been readily detected in other biological matrices, as well as several types of environmental matrices, including surface water, soil and sediments [14] . The predominant analytical approach to measure PFAS in plasma typically involves the use of ultra-high pressure liquid chromatography and tandem mass spectrometry (UHPLC-MS/MS); more specifically, triple quadrupole instrumentation utilizing selected reaction monitoring scanning modalities due to their high sensitivity and selectivity.…”

Section: Methods Detailsmentioning

confidence: 99%

A rapid and simple method to quantify per- and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates

et al. 2020

View full text Add to dashboard Cite

Per- and polyfluoroalkyl substances (PFAS) are synthetic organic compounds that over the past several years, have witnessed a dramatic increase in scientific attention. As PFAS are predominantly accumulated in plasma, monitoring individual burden levels in plasma are typically achieved via some combination of protein precipitation and/or solid phase extraction (SPE), either in online or offline modes. This work describes an updated PFAS extraction workflow, using 96-well plate technology and protein precipitation that is rapid, simple, inexpensive, and amenable for large cohort studies. In brief, plasma proteins were precipitated using methanol and the resulting centrifuged supernatant was directly analyzed using UHPLC-MS/MS. We monitored 51 PFAS, which were quantified via isotope dilution and the effectiveness of the method was demonstrated by using NIST blood-based Standard Reference Materials (SRMs). This method resulted in recoveries ranging between 70 and 89% for all analytes. The 96-well design exhibited low limits of detection and only required sample volumes of 100 µL, thus resulting in an amenable method for high-throughput plasma/serum PFAS screening. • PFAS were directly quantified in plasma and serum samples; • No SPE needed after protein precipitation; • SRMs can be used to validate PFAS measurement in plasma/serum.

show abstract

Section: Methods Detailsmentioning

confidence: 99%

A rapid and simple method to quantify per- and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Some PFAS have relatively long elimination half-lives in the human body, ranging from 2 to 8 y (Li et al 2018;Olsen et al 2007). Unlike many persistent organic pollutants that are lipophilic, PFAS circulate in blood bound to carrier proteins, primarily albumin (Beesoon and Martin 2015;Forsthuber et al 2020).…”

Section: Introductionmentioning

confidence: 99%

Prenatal Exposure to Per- and Polyfluoroalkyl Substances, Umbilical Cord Blood DNA Methylation, and Cardio-Metabolic Indicators in Newborns: The Healthy Start Study

Starling

Liu

Shen

et al. 2020

Environ Health Perspect

View full text Add to dashboard Cite

Background: Per- and polyfluoroalkyl substances (PFAS) are environmentally persistent chemicals widely detected in women of reproductive age. Prenatal PFAS exposure is associated with adverse health outcomes in children. We hypothesized that DNA methylation changes may result from prenatal PFAS exposure and may be linked to offspring cardio-metabolic phenotype. Objectives: We estimated associations of prenatal PFAS with DNA methylation in umbilical cord blood. We evaluated associations of methylation at selected sites with neonatal cardio-metabolic indicators. Methods: Among 583 mother–infant pairs in a prospective cohort, five PFAS were quantified in maternal serum (median 27 wk of gestation). Umbilical cord blood DNA methylation was evaluated using the Illumina HumanMethylation450 array. Differentially methylated positions (DMPs) were evaluated at a false discovery rate and differentially methylated regions (DMRs) were identified using comb-p (Šidák-adjusted ). We estimated associations between methylation at candidate DMPs and DMR sites and the following outcomes: newborn weight, adiposity, and cord blood glucose, insulin, lipids, and leptin. Results: Maternal serum PFAS concentrations were below the median for females in the U.S. general population. Moderate to high pairwise correlations were observed between PFAS concentrations ( ). Methylation at one DMP (cg18587484), annotated to the gene TJAP1 , was associated with perfluorooctanoate (PFOA) at . Comb-p detected between 4 and 15 DMRs for each PFAS. Associated genes, some common across multiple PFAS, were implicated in growth ( RPTOR ), lipid homeostasis ( PON1 , PON3 , CIDEB , NR1H2 ), inflammation and immune activity ( RASL11B , RNF39 ), among other functions. There was suggestive evidence that two PFAS-associated loci (cg09093485, cg09637273) were associated with cord blood triglycerides and birth weight, respectively ( ). Discussion: DNA methylation in umbilical cord blood was associated with maternal serum PFAS concentrations during pregnancy, suggesting potential associations with offspring growth, metabolism, and immune function. Future research should explore whether DNA methylation changes mediate associations between prenatal PFAS exposures and child health outcomes. https://doi.org/10.1289/EHP6888

show abstract

“…Currently, numerous studies by scientists indicate the presence of impaired metabolic activity of the liver due to toxic effects on the body of exogenous and endogenous factors of various origins (Kullak-Ublick et al, 2017;Peter & Prince, 2018;Forsthuber, 2020). Increasingly, information appears in the literature that indicates a growing role of drug factors in the development of relevant nosological forms of hepatopathies (Aithal et al, 2011;Alempijevic & Milosavljevic, 2017;Sanz-Villanueva et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…In fact, this leads to an increase in the value of the A/G ratio. As is known from the literature (Kragh-Hansen et al, 2002;Quinlan et al, 2005;Van der Vusse, 2009;Forsthuber et al, 2020), albumin is the most massive protein fraction of the liquid part of the blood, which by 80% determines its colloidal osmotic pressure, involved in providing a buffer capacity, acts as a reserve of free amino acids in the body and so on. It should be noted that the synthesis of this protein occurs only in hepatocytes and directly depends on the intake of amino acids with food, in particular tryptophan, as well as the presence of ATP, glutathione transferase (Singh et al, 2013) and Mg 2+ ions (Jain & Ducatman, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…They are known to transport numerous exogenous and endogenous metabolites, participate in the binding of hormones, lipids, fat-soluble vitamins, etc. (Van der Vusse, 2009;Forsthuber et al, 2020). Having amphoteric properties, blood plasma proteins play an important role in maintaining the acid-base balance of the body, are blood clotting factors, antibodies (Schroeder & Cavacini, 2010), and are used as a plastic material for their synthesis in tissues (Kragh-Hansen et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Marker changes of blood plasma proteinogram in rats with toxic hepatitis

Gryshchenko

Minina

2020

Regul. Mech. Biosyst.

View full text Add to dashboard Cite

In recent years, there has been a pronounced tendency to increase in the incidence of drug-induced liver damage due to the growing expansion of the pharmaceutical market, which is also observed in the case of incorrect administration of nonsteroidal anti-inflammatory drugs (NSAIDs). In this case, the violation of the functional state of the body has a negative effect on synthetic processes, which in combination with the protein system of tissues significantly affects the metabolic homeostasis of the body. Therefore, the aim of the study was to determine marker changes in the plasma protein spectrum in laboratory rats with diclofenac-induced hepatitis and the effectiveness of reparative therapy based on milk phospholipids. The drug form of toxic hepatitis in laboratory animals was induced according to the author’s model by oral administration of diclofenac sodium (NSAID group) at a dose of 12.5 mg/kg, once a day for 14 days. Thus, in rats with toxic hepatitis there was a probable decrease in plasma total protein content by 15.6% compared with control, indicating a violation of protein-synthesizing function of the liver. With the introduction into the body of clinically healthy and sick animals of the liposomal form of the bioadditive "FLP-MD" based on milk phospholipids, the level of total protein in blood plasma corresponded to control values. As a result of the study of the plasma protein spectrum of Wistar rats, the four most sensitive indicators, which undergo significant probable changes in absolute and relative units of measurement with the development of toxic diclofenac-induced hepatitis, are protein fractions with molecular weights of 180–190, 150–170, 60 and 54–58 kDa and four markers of the effectiveness of restoring the protein-synthesizing function of the liver with the use of corrective therapy, in particular, bioadditives "FLP-MD" – 900, 180–190, 68–70 kDa and the value of A/G ratio, which is important for implementation in applied veterinary medicine, especially in the diagnosis of NSAID hepatopathy, supplementing the picture of its pathogenesis at the molecular level and testing the effectiveness of newly created drugs of hepatoprotective profile.

show abstract

Albumin is the major carrier protein for PFOS, PFOA, PFHxS, PFNA and PFDA in human plasma

Cited by 138 publications

References 31 publications

A rapid and simple method to quantify per- and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates

A rapid and simple method to quantify per- and polyfluoroalkyl substances (PFAS) in plasma and serum using 96-well plates

Prenatal Exposure to Per- and Polyfluoroalkyl Substances, Umbilical Cord Blood DNA Methylation, and Cardio-Metabolic Indicators in Newborns: The Healthy Start Study

Marker changes of blood plasma proteinogram in rats with toxic hepatitis

Contact Info

Product

Resources

About